| MicroRNA-141 suppresses prostate cancer stem cells and metastasis by targeting a cohort of pro-metastasis genes C Liu, R Liu, D Zhang, Q Deng, B Liu, HP Chao, K Rycaj, Y Takata, K Lin, ... Nature communications 8 (1), 14270, 2017 | 208 | 2017 |
| Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses Q Li, Q Deng, HP Chao, X Liu, Y Lu, K Lin, B Liu, GW Tang, D Zhang, ... Nature communications 9 (1), 3600, 2018 | 122 | 2018 |
| CDK7 inhibition suppresses castration-resistant prostate cancer through MED1 inactivation R Rasool, R Natesan, Q Deng, S Aras, P Lal, S Sander Effron, ... Cancer discovery 9 (11), 1538-1555, 2019 | 94 | 2019 |
| Systematic dissection of phenotypic, functional, and tumorigenic heterogeneity of human prostate cancer cells X Liu, X Chen, K Rycaj, HP Chao, Q Deng, C Jeter, C Liu, S Honorio, H Li, ... Oncotarget 6 (27), 23959, 2015 | 75 | 2015 |
| Androgen receptor and prostate cancer stem cells: biological mechanisms and clinical implications Q Deng, DG Tang Endocrine-related cancer 22 (6), T209-T220, 2015 | 69 | 2015 |
| Targeting androgen regulation of TMPRSS2 and ACE2 as a therapeutic strategy to combat COVID-19 Q Deng, R ur Rasool, RM Russell, R Natesan, IA Asangani IScience 24 (3), 2021 | 68 | 2021 |
| LRIG1 is a pleiotropic androgen receptor-regulated feedback tumor suppressor in prostate cancer Q Li, B Liu, HP Chao, Y Ji, Y Lu, R Mehmood, C Jeter, T Chen, JR Moore, ... Nature communications 10 (1), 5494, 2019 | 20 | 2019 |
| CDK7 inhibition suppresses castration-resistant prostate cancer through MED1 inactivation. Cancer Discov. 2019; 9: 1538–1555. doi: 10.1158/2159-8290 RU Rasool, R Natesan, Q Deng, S Aras, P Lal, SS Effron, ... CD-19-0189.[Europe PMC free article][Abstract][CrossRef][Google Scholar], 0 | 8 | |
| Oncofusion-driven de novo enhancer assembly promotes malignancy in Ewing sarcoma via aberrant expression of the stereociliary protein LOXHD1 Q Deng, R Natesan, F Cidre-Aranaz, S Arif, Y Liu, R ur Rasool, P Wang, ... Cell Reports 39 (11), 110971, 2022 | 7 | 2022 |
| Loss of LCMT1 and biased protein phosphatase 2A heterotrimerization drive prostate cancer progression and therapy resistance R Rasool, CM O’Connor, CK Das, M Alhusayan, BK Verma, S Islam, ... Nature Communications 14 (1), 5253, 2023 | 5 | 2023 |
| Targeting transcriptional addiction in anti-androgen refractory castration-resistant prostate cancer R Rasool, R Natesan, Q Deng, S Aras, SS Effron, SS Effron, ... Cancer Research 80 (16_Supplement), 1262-1262, 2020 | | 2020 |
| Discovery and characterization of LOXHD1 as a highly specific EWS-FLI1 driven oncogene in Ewing sarcoma. Q Deng, R Natesan, S Arif, RU Rasool, Y Liu, P Wang, Z Crammer, ... CANCER RESEARCH 80 (11), 54-55, 2020 | | 2020 |
| Abstract B016: CDK7 inhibition suppresses AR addicted Castration-Resistant Prostate Cancer through MED1 inactivation R Rasool, R Natesan, Q Deng, S Aras, P Lal, J Posimo, N Palanisamy, ... Molecular Cancer Therapeutics 18 (12_Supplement), B016-B016, 2019 | | 2019 |
| CDK7 inhibition suppresses castration-resistant prostate cancer through MED1 inactivation R Rasool, R Natesan, Q Deng, S Aras, P Lal, S Sander Effron, ... Cancer discovery 9 (11), 1538-1555, 2019 | | 2019 |
| Abstract LB-097: Linking prostate cancer cell AR heterogeneity to distinct castration and Enzalutamide responses Q Li, X Chen, Q Deng, HP Chao, A Tracz, J Kirk, R Zhao, K Rycaj, ... Cancer Research 78 (13_Supplement), LB-097-LB-097, 2018 | | 2018 |
| ANDROGEN RECEPTOR AND PROSTATE CANCER CELL HETEROGENEITY Q Deng | | 2017 |
